Correct, trofinetide already has priority review. A priority review voucher can be awarded after NDA approval for use with another drug or to be sold on. Obviously the better outcome for Neuren would be for Acadia to sell the voucher.
Acadia, page-13
-
- There are more pages in this discussion • 665 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.98 |
Change
-0.020(0.10%) |
Mkt cap ! $2.553B | |||
| Open | High | Low | Value | Volume |
| $20.05 | $20.28 | $19.82 | $5.032M | 251.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 364 | $19.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.98 | 292 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |